A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma Who Have Acquired Resistance to EGFR–Tyrosine Kinase Inhibitors
Cancer Research and Treatment. 2017;49(1):10-19 
THE EGFR
MUTATION PATTERN AFTER EPIDERMAL GROWTH FACTOR RECEPTOR-TYROSINE KINASE INHIBITORS THERAPY IN PATIENTS WITH NON-SMALL-CELL LUNG CANCER HARBOURING ACTIVATING UNCOMMON EGFR
MUTATIONS
Respirology. 2018;23:286-286
Correction to: Epidermal Growth Factor Receptor (EGFR)–Tyrosine Kinase Inhibitors (TKIs) Combined with Chemotherapy Delay Brain Metastasis in Patients with EGFR‑Mutant Lung Adenocarcinoma
Targeted Oncology. 2019;14(4):491-491
Epidermal growth factor tyrosine kinase inhibitors (EGFR TKIs) and economics
Lung Cancer. 2006;51(1):137-138
Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non-small cell lung cancer
Cancer. 2014;120(15):2289-2298
First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in EGFR Mutation; Positive Non-small Cell Lung Cancer Patients
Journal of Thoracic Oncology. 2008;3(6):S143-S145
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: A new era begins
Cancer Treatment Reviews. 2014;40(1):93-101
Association Of Initial Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment And EGFR Exon 19 Deletion With Frequency Of The T790M Mutation In Non-Small Cell Lung Cancer Patients After Resistance To First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
OncoTargets and Therapy. 2019;Volume 12:9495-9504
M03-02: Molecular predictors for epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): role of egfr gene amplification
Journal of Thoracic Oncology. 2007;2(8):S156-S157
Estrogen Receptor β1 Expression Patterns Have Different Effects on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors’ Treatment Response in Epidermal Growth Factor Receptor Mutant Lung Adenocarcinoma
Frontiers in Oncology. 2021;10: